Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma

Journal of Cutaneous Pathology

Volumn 39, Issue 3, 2012, Pages 324-330

  Ikenberg, Kristian ^a   Pfaltz, Madeleine ^a   Rakozy, Christiane ^a   Kempf, Werner ^a  

^a Kempf and Pfaltz Histological Diagnostics   (Switzerland)

Author keywords

dual staining; Melan A; melanoma; mitosis; phosphohistone H3

Indexed keywords

HISTONE; MELAN A; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; METABOLISM; METHODOLOGY; MIDDLE AGED; MITOSIS; PATHOLOGY; STAINING; STANDARD;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; MITOSIS; NEOPLASM PROTEINS; STAINING AND LABELING;

EID: 84857485248     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2011.01858.x     Document Type: Article

References (16)

1. Balch CM, Gershenwald JE, Soong SJ, et al., Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199.
2. Garbe C, Peris K, Hauschild A, et al., Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46: 270.
3. Attis MG, Vollmer RT., Mitotic rate in melanoma: a reexamination. Am J Clin Pathol 2007; 127: 380.
4. Sekula-Gibbs SA, Shearer MA., Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one. Dermatol Surg 2011; 37: 1080.
5. Puri PK, Valdes CL, Burchette JL, Grichnik JM, Turner JW, Selim MA., Accurate identification of proliferative index in melanocytic neoplasms with Melan-A/Ki-67 double stain. J Cutan Pathol 2010; 37: 1010.
6. Hazan C, Melzer K, Panageas KS, et al., Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer 2002; 95: 634.
7. Colman H, Giannini C, Huang L, et al., Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol 2006; 30: 657.
8. Ribalta T, McCutcheon IE, Aldape KD, Bruner JM, Fuller GN., The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 2004; 28: 1532.
9. Veras E, Malpica A, Deavers MT, Silva EG., Mitosis-specific marker phospho-histone H3 in the assessment of mitotic index in uterine smooth muscle tumors: a pilot study. Int J Gynecol Pathol 2009; 28: 316.
10. Goto H, Tomono Y, Ajiro K, et al., Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem 1999; 274: 25543.
11. Li DW, Yang Q, Chen JT, Zhou H, Liu RM, Huang XT., Dynamic distribution of Ser-10 phosphorylated histone H3 in cytoplasm of MCF-7 and CHO cells during mitosis. Cell Res 2005; 15: 120.
12. Hendzel MJ, Wei Y, Mancini MA, et al., Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997; 106: 348.
13. Shibata K, Inagaki M, Ajiro K., Mitosis-specific histone H3 phosphorylation in vitro in nucleosome structures. Eur J Biochem 1990; 192: 87.
14. Tapia C, Kutzner H, Mentzel T, Savic S, Baumhoer D, Glatz K., Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol 2006; 30: 83.
15. Prade M, Sancho-Garnier H, Cesarini JP, Cochran A., Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma. Int J Cancer 1980; 26: 159.
16. Murali R, Hughes MT, Fitzgerald P, Thompson JF, Scolyer RA., Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma. Ann Surg 2009; 249: 641.